Abstract
In diffuse gastric carcinoma, despite common E-cadherin gene (CDH1) mutations, tumors show absence of CDH1 loss of heterozigosity (LOH) in most cases. This observation challenges the classical two-hit model of tumor suppressor gene inactivation. In order to investigate whether or not CDH1 promoter methylation may function as the second hit we analysed a series of 23 sporadic gastric carcinomas for the presence of CDH1 mutations, CDH1 promoter methylation, LOH and E-cadherin expression. CDH1 mutations were detected in nine of the 16 (56.3%) diffuse gastric carcinomas and in none of the seven intestinal gastric carcinomas. In diffuse gastric carcinomas harboring CDH1 mutations, LOH was observed in a single case. Loss of plasma membrane E-cadherin expression was consistently found in all nine cases with CDH1 mutation, suggesting that tumors inactivated the remaining CDH1 allele via a different mechanism. CDH1 promoter methylation was observed in nine of the 16 (56.3%) diffuse-type gastric carcinoma cases, including six of the nine cases (66.7%) harboring CDH1 mutations. CDH1 promoter methylation was also seen in two (28.6%) intestinal-type cases. Our results show that CDH1 promoter methylation is the second hit in more than half of the sporadic diffuse gastric carcinoma cases harboring CDH1 mutations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H . 1994 Cancer Res. 54: 3845–3852
Berx G, Becker KF, Hofler H, van Roy F . 1998 Hum. Mutat. 12: 226–237
Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F . 1995 EMBO J. 14: 6107–6115
Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, Cornelisse C . 1996 Oncogene 13: 1919–1925
Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, Machado JC, Pinto E, Seruca R, Halling K, MacLeod P, Powell SM, Jackson CE, Ponder BAJ, Caldas C . 1998 Cancer Res. 58: 4086–4089
Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S . 2000 Nat. Genet. 26: 16–17
Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG . 2000 J. Biol. Chem. 275: 2727–2732
Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB . 1995 Cancer Res. 55: 5195–5199
Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM . 1997 J. Biol. Chem. 272: 22322–22329
Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE . 1998 Nature 392: 402–405
Handschuh G, Candidus S, Luber B, Reich U, Schott C, Oswald S, Becke H, Hutzler P, Birchmeier W, Hofler H, Becker KF . 1999 Oncogene 18: 4301–4312
Hennig G, Behrens J, Truss M, Frisch S, Reichmann E, Birchmeier W . 1995 Oncogene 11: 475–484
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826
Iida S, Akiyama Y, Nakajima T, Ichikawa W, Nihei Z, Sugihara K, Uasa Y . 2000 Int. J. Cancer 87: 654–658
Kang SH, Bang YJ, Im YH, Yang HK, Lee DA, Lee HY, Lee HS, Kim NK, Kim SJ . 1999 Oncogene 18: 7280–7286
Lee YY, Kang SH, Seo JY, Jung CW, Lee KU, Choe KJ, Kim BK, Kim NK, Koeffler HP, Bang YJ . 1997 Cancer 80: 1889–1896
Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC . 1999 Cancer Res. 59: 159–164
Luber B, Candidus S, Handschuh G, Mentele E, Hutzler P, Feller S, Voss J, Hofler H, Becker KF . 2000 Cell Adhes. Commun. 7: 391–408
Machado JC, Carneiro F, Beck S, Rossi S, Lopes J, Taveira-Gomes A, Cardoso-Oliveira M . 1998 Int. J. Surg. Pathol. 6: 135–144
Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N, Berx G, Sobrinho-Simöes M . 1999 Lab. Invest. 79: 459–465
Shin JY, Kim HS, Park J, Park JB, Lee JY . 2000 Cancer Res. 60: 262–265
Takeichi M . 1991 Science 251: 1451–1455
Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Tershima M, Motoyama T, Meltzer SJ . 2000 J. Natl. Cancer Inst. 92: 569–573
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Machado, J., Oliveira, C., Carvalho, R. et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 20, 1525–1528 (2001). https://doi.org/10.1038/sj.onc.1204234
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204234
Keywords
This article is cited by
-
Neural crest E-cadherin loss drives cleft lip/palate by epigenetic modulation via pro-inflammatory gene–environment interaction
Nature Communications (2023)
-
Indolent feature of Helicobacter pylori-uninfected intramucosal signet ring cell carcinomas with CDH1 mutations
Gastric Cancer (2021)
-
CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer
BMC Cancer (2019)
-
Early Hereditary Diffuse Gastric Cancer (eHDGC) is Characterized by Subtle Genomic Instability and Active DNA Damage Response
Pathology & Oncology Research (2019)
-
Novel Variants and Copy Number Variation in CDH1 Gene in Iranian Patients with Sporadic Diffuse Gastric Cancer
Journal of Gastrointestinal Cancer (2019)